TheraPanacea
Nikos Paragios has a diverse work experience that spans over several prestigious institutions and companies. Nikos is currently a Distinguished Professor of Mathematics at Université Paris-Saclay, a position they have held since January 2020. Prior to this, Paragios served as the President and Chief Executive Officer of TheraPanacea starting in January 2018. Nikos was also a Distinguished Professor of Mathematics at CentraleSupélec from November 2005 onwards. Paragios has been a member of the Scientific Council at Safran since September 2012. Furthermore, they have actively contributed to the field of data sciences and business analytics as the Co-Director of ESSEC - CentraleSupélec's Master's program in this field since September 2014. Paragios serves as a Board Member for nuclivision since June 2022 and for Artedrone since April 2019. Notably, they held the prestigious position of Editor in Chief at Elsevier starting in January 2014, a role they will continue until December 2022. Paragios also served as the Scientific Leader of Inria's Galen team from February 2008 to January 2018. Finally, they were a Professor at Ecole des Ponts ParisTech from October 2011 to September 2013.
Nikos Paragios completed their Bachelor's Degree in Computer Science at the University of Crete from 1990 to 1994. Nikos then pursued a Master's Degree in Computer Science at the University of Crete from 1994 to 1996. Following this, they attended Université Côte d'Azur, where they obtained a Doctor of Philosophy (Ph.D.) in Electrical and Computer Engineering from 1996 to 2000. Lastly, they completed their education with a Habilitation à diriger des recherches (HDR) in Engineering from Université Côte d'Azur between 2000 and 2005.
TheraPanacea
TheraPanacea is an innovative information technology company devoted to unlocking the power of AI-based solutions to drive innovation in healthcare. A spin-off of University Paris-Saclay, TheraPanacea works in close cooperation with the most prominent healthcare facilities to combine the power of its proprietary platforms with clinical domain-knowledge. Today, ART-Plan™, TheraPanacea dedicated suite for radio-oncology, is used by more than 60 cancer centres across Europe, Africa, Middle-East and the US and is helping to improve care for more than 60,000 patients every year. TheraPanacea also develops and operates the ART-Omics™ platform enabling pharmaceutical companies to accelerate clinical research by harnessing AI-based multi-modality biomarker discovery in clinical trials and their effective integration within the clinical workflow at scale in the form of certified medical devices.